Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jun 11, 2024 12:13pm
99 Views
Post# 36082924

RE:Another Proof Shiseido will commercialize hair regeneration

RE:Another Proof Shiseido will commercialize hair regenerationMetzger I think it is a leap of faith to think that this job search by Shiseido you have found proves that they are going to proceed to take Replicel's technology to market.  I think we would all love to see that because it would  give value to Replicel's rights to this hair procedure for all coiuntries outside of Asia.

The key element for me is Andrew Schutte is investing even more money into Replicel over and above the 17,401,616 shares he holds that has at least cost him 2-3 million $$.  The question is why he is pumping more money into this if there is no future return on his investment.  Then you have to ask the question: where will the ROI come from ?  Is it the dermal injector ?  Is there some large Pharma interested in buying the company as a whole ?  Lastly in his LOI he mentions developing the assets which will take years.  I rule that out.   A.S. is holding his cards close to his face at this point.  We have no idea of what he has planned.
Hopefully we get some clarity on this as I am sure we are all tired of waiting.
<< Previous
Bullboard Posts
Next >>